HC Wainwright Reiterates Neutral Rating for Agenus (NASDAQ:AGEN)

HC Wainwright restated their neutral rating on shares of Agenus (NASDAQ:AGEN) in a report released on Tuesday,Benzinga reports. HC Wainwright also issued estimates for Agenus’ Q1 2025 earnings at ($1.85) EPS, Q2 2025 earnings at ($1.26) EPS, Q3 2025 earnings at ($0.90) EPS, Q4 2025 earnings at ($0.61) EPS, FY2025 earnings at ($4.37) EPS, FY2026 earnings at ($3.79) EPS, FY2027 earnings at ($3.25) EPS, FY2028 earnings at ($3.48) EPS and FY2029 earnings at ($2.32) EPS.

Separately, Robert W. Baird reduced their price objective on Agenus from $6.00 to $3.00 and set a “neutral” rating for the company in a report on Wednesday, March 12th. One analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $8.75.

Agenus Stock Performance

Shares of AGEN stock opened at $1.67 on Tuesday. The stock has a fifty day moving average price of $3.04 and a 200 day moving average price of $3.70. The stock has a market cap of $39.18 million, a PE ratio of -0.15 and a beta of 1.23. Agenus has a 1 year low of $1.64 and a 1 year high of $19.69.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings data on Tuesday, March 11th. The biotechnology company reported ($2.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.36) by $0.32. The firm had revenue of $26.84 million for the quarter, compared to analyst estimates of $30.09 million. As a group, equities research analysts predict that Agenus will post -12.55 earnings per share for the current year.

Hedge Funds Weigh In On Agenus

A number of institutional investors have recently made changes to their positions in the stock. Barclays PLC raised its holdings in shares of Agenus by 17.7% in the fourth quarter. Barclays PLC now owns 32,737 shares of the biotechnology company’s stock worth $90,000 after acquiring an additional 4,924 shares during the last quarter. HighTower Advisors LLC raised its holdings in shares of Agenus by 46.1% in the third quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock worth $122,000 after acquiring an additional 7,530 shares during the last quarter. State Street Corp grew its position in shares of Agenus by 2.1% in the third quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock valued at $2,563,000 after purchasing an additional 9,731 shares during the period. EP Wealth Advisors LLC purchased a new stake in shares of Agenus in the third quarter valued at $55,000. Finally, Point72 DIFC Ltd grew its position in shares of Agenus by 380.0% in the third quarter. Point72 DIFC Ltd now owns 14,579 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 11,542 shares during the period. 61.46% of the stock is owned by institutional investors and hedge funds.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.